Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FGEN FibroGen	$5.69 +8.4%	$7.25	$4.50 ▼ $38.25	$21.22M	0.74	76,019 shs	33,072 shs
MCRB Seres Therapeutics	$11.36 +4.6%	$8.24	$6.53 ▼ $30.60	$94.83M	2.75	134,800 shs	107,170 shs
MDGL Madrigal Pharmaceuticals	$298.49 -0.6%	$291.84	$200.63 ▼ $377.46	$6.66B	-1.05	358,926 shs	108,674 shs
MGNX MacroGenics	$1.44 +4.3%	$1.50	$0.99 ▼ $5.77	$87.07M	1.59	844,403 shs	699,979 shs
PRLD Prelude Therapeutics	$0.81 +1.3%	$0.90	$0.61 ▼ $6.80	$45.17M	1.22	290,888 shs	87,143 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FGEN FibroGen	-0.38%	-8.06%	-28.52%	-28.64%	-71.74%
MCRB Seres Therapeutics	+1.50%	+14.20%	+55.14%	-21.03%	-22.54%
MDGL Madrigal Pharmaceuticals	0.00%	+8.11%	+10.08%	-8.24%	+10.48%
MGNX MacroGenics	+9.52%	+5.34%	-0.72%	+20.00%	-66.34%
PRLD Prelude Therapeutics	0.00%	-6.41%	-11.81%	+12.98%	-78.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FGEN FibroGen	4.7135 of 5 stars	3.3	3.0	4.7	4.4	3.3	0.6
MCRB Seres Therapeutics	3.0655 of 5 stars	2.9	2.0	4.6	0.6	0.8	0.0
MDGL Madrigal Pharmaceuticals	4.0777 of 5 stars	3.4	0.0	4.6	2.1	3.3	0.6
MGNX MacroGenics	4.1213 of 5 stars	3.2	3.0	4.4	1.1	2.5	0.6
PRLD Prelude Therapeutics	3.4575 of 5 stars	3.5	4.0	0.0	0.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FGEN FibroGen	2.50	Moderate Buy	$250.00	4,293.67% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	548.76% Upside
MDGL Madrigal Pharmaceuticals	2.89	Moderate Buy	$420.63	40.92% Upside
MGNX MacroGenics	2.40	Hold	$5.71	296.83% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.50	455.56% Upside

Current Analyst Ratings Breakdown

Latest FGEN, MCRB, PRLD, MGNX, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/2/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$441.00 ➝ $458.00
5/2/2025	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$422.00 ➝ $460.00
5/2/2025	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$394.00 ➝ $420.00
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00
4/24/2025	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$443.00 ➝ $443.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FGEN FibroGen	$29.62M	0.78	N/A	N/A	($50.89) per share	-0.11
MCRB Seres Therapeutics	$126.32M	0.78	N/A	N/A	$1.61 per share	7.05
MDGL Madrigal Pharmaceuticals	$180.13M	36.79	N/A	N/A	$34.59 per share	8.63
MGNX MacroGenics	$149.96M	0.61	N/A	N/A	$1.85 per share	0.78
PRLD Prelude Therapeutics	$7M	6.53	N/A	N/A	$2.39 per share	0.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$465.89M	-$18.05	N/A	N/A	N/A	-123.38%	-50.54%	-37.19%	8/6/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)
PRLD Prelude Therapeutics	-$127.17M	-$1.69	N/A	N/A	N/A	N/A	-89.18%	-69.26%	8/11/2025 (Estimated)

Latest FGEN, MCRB, PRLD, MGNX, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FGEN FibroGen	N/A	2.02	1.98
MCRB Seres Therapeutics	N/A	2.11	2.11
MDGL Madrigal Pharmaceuticals	0.17	5.91	5.58
MGNX MacroGenics	N/A	3.28	3.11
PRLD Prelude Therapeutics	N/A	5.18	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FGEN FibroGen	72.71%
MCRB Seres Therapeutics	59.34%
MDGL Madrigal Pharmaceuticals	98.50%
MGNX MacroGenics	96.89%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
FGEN FibroGen	3.07%
MCRB Seres Therapeutics	4.70%
MDGL Madrigal Pharmaceuticals	21.50%
MGNX MacroGenics	13.00%
PRLD Prelude Therapeutics	63.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable

FGEN, MCRB, PRLD, MGNX, and MDGL Headlines

Recent News About These Companies

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC

June 8, 2025 | marketbeat.com

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025

June 3, 2025 | msn.com

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025 | globenewswire.com

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges

May 28, 2025 | investing.com

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

May 15, 2025 | fiercebiotech.comF

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs

May 10, 2025 | msn.com

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025

May 4, 2025 | msn.com

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies

April 30, 2025 | msn.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

Prelude Therapeutics CEO buys $467K in common stock

March 28, 2025 | markets.businessinsider.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in Stock

March 28, 2025 | insidertrades.com

Prelude Therapeutics stock surges on insider buying

March 27, 2025 | investing.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 Shares

March 15, 2025 | insidertrades.com

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements

March 14, 2025 | msn.com

Analysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)

March 12, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FGEN, MCRB, PRLD, MGNX, and MDGL Company Descriptions

FibroGen NASDAQ:FGEN

$5.69 +0.44 (+8.38%)

Closing price 03:52 PM Eastern

Extended Trading

$5.61 -0.08 (-1.41%)

As of 04:56 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Seres Therapeutics NASDAQ:MCRB

$11.36 +0.50 (+4.56%)

Closing price 03:57 PM Eastern

Extended Trading

$11.94 +0.58 (+5.11%)

As of 04:52 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Madrigal Pharmaceuticals NASDAQ:MDGL

$298.48 -1.67 (-0.55%)

Closing price 03:39 PM Eastern

Extended Trading

$298.48 0.00 (0.00%)

As of 04:09 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

MacroGenics NASDAQ:MGNX

$1.44 +0.06 (+4.35%)

As of 03:37 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Prelude Therapeutics NASDAQ:PRLD

$0.81 +0.01 (+1.25%)

As of 02:45 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time